Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

ATA Risk Stratification (Thyroid)

The American Thyroid Association (ATA) Risk Stratification System classifies patients with Differentiated Thyroid Cancer (Papillary/Follicular) into Low, Intermediate, or High risk of structural disease recurrence.

Evidence-based context for fast calculator use

Purpose:
ATA risk stratification classifies differentiated thyroid cancer recurrence risk to guide post-surgical surveillance and TSH suppression targets.
Population:
patients with differentiated thyroid cancer pathology in the staging or recurrence-risk setting described by the model
Factors:
Distant Metastases?, Gross Extrathyroidal Extension OR Incomplete Resection?, Microscopic Extrathyroidal Extension?, Lymph Node Metastases?, Aggressive Histology?, Vascular Invasion?
Reference:
Haugen BR, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133.
HomeATA Risk Stratification (Thyroid)
Pin your most used calculators here by clicking the star in the dropdown.

ATA Risk Stratification (Thyroid)

Clinical Context & Background

The American Thyroid Association (ATA) Risk Stratification System classifies patients with Differentiated Thyroid Cancer (Papillary/Follicular) into Low, Intermediate, or High risk of structural disease recurrence. This helps tailor post-operative monitoring and TSH suppression targets.
Primary Source EvidenceHaugen BR, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133.
Formula Logic
Classification based on pathology features (Invasion, Mets, Resection, Histology).

Reference Data

Risk GroupEst. Recurrence RiskTSH Goal
Low Risk< 5%0.5 - 2.0 mIU/L (or 0.1-0.5 if aggressive)
Intermediate Risk10 - 20%0.1 - 0.5 mIU/L
High Risk> 30%< 0.1 mIU/L

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use ATA Risk Stratification (Thyroid) when aTA risk stratification classifies differentiated thyroid cancer recurrence risk to guide post-surgical surveillance and TSH suppression targets.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Low Risk through High Risk.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm histology, age, tumor size, invasion, nodal and distant disease, resection status, molecular findings, and guideline system.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Mortality staging, recurrence-risk classification, and postoperative response assessment are different frameworks.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with differentiated thyroid cancer pathology in the staging or recurrence-risk setting described by the model

How to apply this result

For a representative case, verify Distant Metastases?, Gross Extrathyroidal Extension OR Incomplete Resection?, Microscopic Extrathyroidal Extension?, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Share This Calculator

Share:

Related Tools

MACIS Score (Thyroid)

Frequently Asked Questions

When should ATA Risk Stratification (Thyroid) be used?

Use it for patients with differentiated thyroid cancer pathology in the staging or recurrence-risk setting described by the model when all required inputs and the intended clinical setting are confirmed.

Can ATA Risk Stratification (Thyroid) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.